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Abstract
Purpose: Aberrant PI3K/AKT/mTOR signaling has been linked to oncogenesis and therapy resistance in various
malignancies  including  leukemias.  In  Philadelphia  chromosome  (Ph)  positive  leukemias,  activation  of  PI3K  by
dysregulated BCR-ABL tyrosine kinase (TK) contributes to the pathogenesis and development of resistance to ABL-
TK inhibitors (TKI). The PI3K pathway thus is an attractive therapeutic target in BCR-ABL positive leukemias, but its
role in BCR-ABL negative ALL is conjectural. Moreover, the functional contribution of individual components of the
PI3K pathway in ALL has not been established.
Experimental  Design:  We  compared  the  activity  of  the  ATP-competitive  pan-PI3K  inhibitor  NVP-BKM120,  the
allosteric mTORC1 inhibitor RAD001, the ATP-competitive dual PI3K/mTORC1/C2 inhibitors NVP-BEZ235 and NVP-
BGT226 and the combined mTORC1 and mTORC2 inhibitors Torin 1, PP242 and KU-0063794 using long-term
cultures  of  ALL  cells  (ALL-LTC)  from  patients  with  B-precursor  ALL  that  expressed  the  BCR-ABL  or  TEL-ABL
oncoproteins or were BCR-ABL negative.
Results: Dual PI3K/mTOR inhibitors profoundly inhibited growth and survival of ALL cells irrespective of their genetic
subtype and their responsiveness to ABL-TKI. Combined suppression of PI3K, mTORC1 and mTORC2 displayed
greater antileukemic activity than selective inhibitors of PI3K, mTORC1 or mTORC1 and mTORC2.
Conclusions:  Inhibition  of  the  PI3K/mTOR  pathway  is  a  promising  therapeutic  approach  in  patients  with  ALL.
Greater antileukemic activity of dual PI3K/mTORC1/C2 inhibitors appears to be due to the redundant function of PI3K
and  mTOR.  Clinical  trials  examining  dual  PI3K/mTORC1/C2  inhibitors  in  patients  with  B-precursor  ALL  are
warranted, and should not be restricted to particular genetic subtypes.
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Introduction
The Phosphatidylinositol 3-kinase (PI3K) signaling pathway
plays  an  important  role  in  many  physiological  functions,
including  cell  cycle  progression,  differentiation,  survival,
apoptosis  and  protein  synthesis  [1,2].  Dysregulated  PI3K
signaling  has  been  linked  to  oncogenesis  and  disease
progression  in  a  variety  of  solid  tumors  and  hematologic
malignancies  and  appears  to  enhance  resistance  to
antineoplastic  therapy,  resulting  in  a  poor  prognosis  [1–4].
Aberrant  PI3K/AKT  activation  has  been  reported  in  50%  to
80% of acute myeloid leukemias (AML), up to 88% of acute T-
lymphoblastic  leukemias  (ALL),  and  in  chronic  myeloid
leukemia (CML) [5–7]. In CML, activation of the PI3K pathway
has been linked to the BCR-ABL tyrosine kinase, the hallmark
of CML which is also present in approximately 25% of adult
ALL patients, coinciding with the presence of the Philadelphia
(Ph) chromosome [3,8,9]. The prognosis of patients with Ph+
ALL  remains  poor  and  is  limited  by  the  development  of
secondary resistance to ABL-directed tyrosine kinase inhibitors
(TKI),  caused  predominantly  by  BCR-ABL  tyrosine  kinase
domain (TKD) mutations that prevent the TKI-induced inhibition
of  BCR-ABL  activity  [8,10–12].  This  results  in  continued
activation of multiple signaling pathways downstream of BCR-
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accepted involvement in BCR-ABL mediated leukemogenesis
[3,6,13,14].  Activation  of  the  PI3K/AKT/mTOR  pathway  has
also been shown to be involved in non-mutational resistance of
BCR-ABL expressing cells to the ABL-directed tyrosine kinase
inhibitor imatinib [15,16]. While these data make a compelling
case for targeting the PI3K pathway as a therapeutic strategy
for Ph+ ALL, its potential pathophysiologic role and value as a
therapeutic target in BCR-ABL negative B-lineage ALL remain
largely unexplored.
Activation of PI3K leads to the phosphorylation of AKT on
Thr308, which in turn induces activation of mammalian target of
rapamycin (mTOR), a distal element of the PI3K/AKT/mTOR
pathway  [2,17,18].  mTOR  is  a  serine/threonine  kinase  that
encompasses two distinct complexes, mTORC1 and mTORC2,
which  differ  structurally,  in  their  substrate  specificity  and
functionally [18,19]. mTORC1 is known to induce cell growth in
response  to  nutrients  and  growth  factors  by  regulating  the
translational regulators S6K1 and 4E-BP1, whereas mTORC2
mediates cell proliferation and survival by phosphorylating AKT
on Ser473 to facilitate its full activation [17,18,20–24].
The relative contributions of the individual components of the
PI3K/AKT/mTOR  signaling  pathway  for  proliferation  and
survival in the cellular context of ALL remain to be resolved.
Combined inhibition of PI3K and the mTOR complexes 1 and 2
may have the advantage to inhibit feedback loops and may be
more efficient than targeting PI3K and mTORC1 alone.
A  number  of  inhibitors  of  PI3K/AKT/mTOR  signaling  have
been  developed  that  selectively  interfere  with  different
components of this pathway, and thus differ in their biological
effects.  The  allosteric  mTORC1  inhibitors  rapamycin  and
RAD001 display primarily antiproliferative effects in vitro and in
vivo,  with  slowing  of  tumor  growth  and  delayed  progression,
but are poor inducers of apoptosis. One reason for this appears
to  be  the  simultaneous  activation  of  feedback  loops  in
conjunction with inhibition of mTORC1, resulting in survival of
cells [25–33].
As PI3K signaling is considered to be one of the decisive
pathways  for  the  transformation  potential  of  BCR-ABL,  and
may play a role in causing imatinib-resistance, we investigated
the antileukemic effects of PI3K, mTORC1 and combined PI3K,
mTORC1  and  mTORC2  inhibition  in  BCR-ABL/TEL-ABL
positive and negative LTCs.
We  utilized  several  inhibitors  that  are  currently  in  clinical
testing,  including  the  ATP-competitive  selective  pan-PI3K
inhibitor  NVP-BKM120,  the  dual  PI3K  and  mTOR  inhibitors
NVP-BEZ235 and NVP-BGT226, and the allosteric mTORC1
inhibitor  RAD001[34–37].  We  examined  the  following  issues
related to the potential anti-leukemic activity of PI3K pathway
inhibition: i) Susceptibility of BCR-ABL positive ALL resistant to
ABL-directed TKI to PI3K pathway inhibitors ii) Comparison of
TEL-ABL positive with BCR-ABL positive ALL cells in terms of
the functional relevance of PI3K signaling, iii) Activity of PI3K
pathway  inhibitors  against  BCR-ABL  negative  ALL  iv)
Assessment  of  the  relative  contribution  of  the  different
components  of  the  PI3K  pathway  to  leukemia  growth  and
survival, and v) utility of assessing the phosphorylation status
of  AKT,  S6  and  4E-BP1  as  biomarkers  for  responsiveness
among different leukemic subtypes
Materials and Methods
ALL-LTCs, cells and reagents
Initiation  of  a  LTC  from  a  BCR-ABL  positive  ALL  patient
harboring  the  T315I  mutation  was  performed  essentially  as
previously  described  [38].  Briefly,  leukemic  blasts  that  had
been  collected  from  the  bone  marrow  of  a  patient  following
development  of  resistance  to  dasatinib  were  cryopreserved
after  Ficoll  density  centrifugation,  thawed  and  placed  into
serum-free culture medium. Viable cells were maintained at a
density ranging from 0.5 to 2x106 cells/ml. After an initial lag
phase, proliferation ensued resulting in prolonged expansion of
cultured cells. For all functional assays described herein, only
cells  that  had  been  passaged  for  less  than  6  months  were
used.  All  other  ALL-LTCs  from  patients  with  BCR-ABL/TEL-
ABL  positive  and  negative  B-precursor  ALL  have  been
described previously [38,39]. The LTCs showed largely stable
karyotypes and immune phenotypes after 6 months in culture
when  compared  to  the  corresponding  primary  cells.  None  of
these 6 BCR-ABL positive LTCs harbored mutations in the ABL
tyrosine  kinase  domain.  Jurkat  cells  were  obtained  from  the
German  Collection  of  Microorganisms  and  Cell  Cultures
(DSMZ,  Braunschweig,  Germany)  and  maintained  in
RPMI-1640 medium supplemented with 10% fetal calf serum
(FCS)  (Invitrogen,  Karlsruhe,  Germany).  Imatinib,  nilotinib
(BCR-ABL inhibitors), NVP-BKM120 (PI3K inhibitor), RAD001
(mTORC1  inhibitor),  NVP-BGT226,  and  NVP-BEZ235  (PI3K/
mTORC1/2  inhibitors)  were  kindly  provided  from  Novartis,
Basel,  Switzerland.  LY294002  and  Wortmannin  (PI3K
inhibitors) were obtained from Sigma, Steinheim, Germany, the
mTORC1/C2 inhibitors Torin 1, PP242 and KU-0063794 were
purchased  from  Selleck  Chemicals  (Munich,  Germany)  and
dasatinib (BCR-ABL inhibitor) was kindly provided from Bristol-
Myers Squibb, Munich, Germany.
Proliferation assay
Cell proliferation was assessed using the Cell Proliferation
Kit  II  (XTT)  (Roche,  Mannheim,  Germany)  according  to  the
manufacturer´s  instructions.  Cells  were  seeded  at  a
concentration  of  0.5x106  cells/ml,  and  proliferation  was
measured  on  day  4.  Cell  division  of  the  LTC  KÖ  was
determined  by  trypan  blue  dye  exclusion  assay  using  a
Countess® Cell Counter (Invitrogen).
Assay for cell death
Cell  death  was  quantified  using  the  Annexin-V-FLUOS
Staining  Kit  (Roche,  Mannheim,  Germany)  according  to  the
manufacturer´s  instructions.  Cells  were  seeded  at  a
concentration of 0.5x106 cells/ml and cell death was measured
on  day  4.  Cell  death  was  defined  as  positive  staining  for
Annexin-V and/or propidium iodide by flow cytometry.
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Western  blot  analyses  were  performed  using  the  NuPage
Western  blotting  system  (Invitrogen)  according  to  the
manufacturer´s  instructions.  The  following  antibodies  were
used: anti-phosphorylated AKT specific for the phosphorylated
serine  residue  473  (p-AKT-S473),  anti-AKT  (AKT),  anti-
phosphorylated  S6  protein  specific  for  the  phosphorylated
serine  residues  235/236  (p-S6-S235/236)  and  240/244  (p-
S6-240/244) anti-S6 (S6), anti-phosphorylated 4E-BP1, specific
for the phosphorylated threonine residues Thr37/46 (p-4EB-P1-
Thr37/46), anti-4E-BP1 (4E-BP1) and anti-β-Actin (β-Actin). All
antibodies  were  obtained  from  Cell  Signaling  Technology,
Danvers,  MA.  Membrane  blocking  and  antibody  incubation
were  performed  in  5%  low-fat  dry  milk  and  5%  BSA,
respectively, and the membranes were washed in Tris-buffered
saline  (TBS)  (10mM  Tris-HCl  pH8,  150nM  NaCl)  containing
0.1%  Tween-20  (TBST).  The  antibodies  were  diluted  in  5%
BSA and 5% low-fat dry milk, respectively.
Statistical analysis
Differences in response rate of BCR-ABL+/TEL-ABL+ versus
BCR-ABL-  LTCs  towards  the  same  concentration  of  single
inhibitors were analyzed by Student's t-test. Statistical analyses
were  performed  using  the  GraphPad  Prism  (GraphPad
Software, San Diego, CA) software package.
Results
Characterization of a newly established BCR-ABL
positive human ALL-LTC harboring the T315I mutation
After the initial lag period, blast cells in the ALL-LTC KÖ had
a  doubling  time  of  approximately  3  days.  Surface  marker
expression demonstrated expression of CD19, CD79a, CD22,
CD20,  CD10,  CD34,  HLA-DR,  TdT  and  CD13  (data  not
shown).  Cytogenetic  analysis  at  diagnosis  revealed  the
following  complex  karyotype:  53,XX,del(1)(q25),+der(2)t(2;8)
(q21;?),+6,der(9)t(1;9)(?;p22)t(9;22)(q34;q11),+14,+
der(18)t(1;18)(?;p11),+21+21,der(22)t(9;22)
(q34;q11),der(22)t(9;22)(q34;q11).  Mutation  analysis  of
leukemic  cells  prior  to  and  during  culture  demonstrated  the
presence of the BCR-ABL TKD gatekeeper mutation T315I. As
expected,  KÖ  cells  were  unresponsive  to  imatinib,  dasatinib
and nilotinib when used at clinically achievable concentrations,
known  to  inhibit  proliferation  and  induce  cell  death  in  non-
resistant BCR-ABL+ cells. The BCR-ABL+ LTC PH served as
positive control (Figure 1A and 1B).
BCR-ABL+ LTCs display variable responsiveness to
TKI with concordance between imatinib, nilotinib and
dasatinib
Functional in vitro analyses of mutational and non-mutational
TKI-resistance of BCR-ABL+ ALL have relied on leukemic cell
lines, given the lack of cell culture models using primary ALL
cells.  We  employed  the  6  ALL-LTC  without  TKD  mutations
described above to determine whether the cells differed in their
innate responsiveness to the clinically available TKI imatinib,
dasatinib  and  nilotinib,  facilitating  further  studies  of  non-
mutational  resistance.  Five  of  the  7  LTCs,  demonstrated  a
dose–dependent but variable responsiveness to the TKI, one
LTC (BV) was resistant despite no evidence of a TKD mutation
(Figure 1C). The presence of the T315I mutation in KÖ cells
was associated with resistance to all three TKI, as described
above.  Based  on  the  antiproliferative  and  proapoptotic
response  (at  1µM  imatinib,  250µM  nilotinib  and  25nM
dasatinib,  i.e.  at  plateau  concentrations)  we  operationally
classified the ALL-LTCs as highly sensitive (PH), intermediate
sensitive (CM, DW, KW and VB), and resistant (KÖ and BV).
While nilotinib and dasatinib where more potent than imatinib,
the degree of TKI response was independent of the TKI used
(Figure 1C).
Taken  together,  these  ALL-LTCs  recapitulate  the  different
responses to TKI observed in patients, and represent the first
suitable model for investigating mechanisms of non-mutational
TKI  resistance  in  BCR-ABL+  ALL,  as  well  as  for  examining
strategies to overcome this type of resistance.
Impact of BCR-ABL and TEL-ABL activity on AKT and
mTOR as downstream targets of PI3K
BCR-ABL  activates  numerous  signaling  pathways  and
thereby regulates cell proliferation and survival. The PI3K/AKT/
mTOR pathway is considered to play a central role in BCR-ABL
as  well  as  in  TEL-ABL  induced  leukemogenesis  [3,6,40].  To
examine whether inhibition of BCR-ABL and TEL-ABL kinase
activity suppresses PI3K signaling, ALL-LTCs were exposed to
imatinib at 1µM for 20h and phosphorylation levels of AKT, S6
protein and 4E-BP1 were determined. AKT phosphorylation at
Ser473  was  detected  in  all  ALL-LTCs,  irrespectively  of  the
presence  or  absence  of  BCR-ABL  or  TEL-ABL,  respectively
(Figure 2). Unexpectedly, inhibition of BCR-ABL and TEL-ABL
kinase activity did not result in dephosphorylation of AKT. To
determine  whether  components  of  the  PI3K  pathway
downstream  of  AKT  were  affected  by  inhibition  of  ABL,  we
analyzed the phosphorylation levels of the S6 protein and 4E-
BP1. Phosphorylation of the S6 protein was more pronounced
in untreated TEL-ABL+ LTC (VG) than in untreated BCR-ABL+
LTCs. In 3 of 7 LTCs with an ABL-rearrangement (2/6 BCR-
ABL,  1/1  TEL-ABL)  inhibition  by  imatinib  resulted  in
dephosphorylation of the S6 protein, a well-established marker
for the activity of mTORC1. In contrast, no dephosphorylation
of 4E-BP1 was observed following exposure to imatinib in any
of these cells (Figure 2).
Thus,  phosphorylation  of  AKT  appears  to  be  a  common
feature of B-precursor ALL and is not restricted to ALL cells
with  an  ABL  translocation.  Moreover,  the  level  of  AKT
phosphorylation  does  not  depend  on  the  tyrosine  kinase
activity  of  ABL,  indicating  that  ABL-directed  TKI  exert  their
biologic effects through other components of the PI3K signaling
pathway. Our observation that inhibition of BCR-ABL or TEL-
ABL resulted in dephosphorylation of the S6 protein in only 3 of
7 cases (2/6 BCR-ABL, 1/1 TEL-ABL), and that the extent of
imatinib-induced S6 dephosphorylation does not correlate with
the sensitivity of the BCR-ABL+ ALL-LTCs to imatinib, point to
an  unexpected  heterogeneity  in  mechanisms  of  TKI-induced
inhibition.
PI3K Pathway in Acute Lymphoblastic Leukemia
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The commonly accepted role of PI3K/AKT/mTOR as a major
downstream  signaling  pathway  of  BCR-ABL  and  TEL-ABL
suggested that cells harboring an ABL-translocation might be
more  sensitive  to  inhibition  of  this  pathway  than  BCR-ABL
negative  cells.  In  addition,  we  were  interested  whether  the
variable sensitivity of the BCR-ABL+ LTCs to ABL-directed TKI
was associated with a differential responsiveness to inhibition
of the PI3K/AKT/mTOR pathway.
In all LTCs, the selective PI3K inhibitors NVP-BKM120 and
LY294002 inhibited cell proliferation and induced cell death in a
dose-dependent  manner,  although  the  sensitivity  to  PI3K
inhibition  varied  (Figure  3A  and  3B).  Unexpectedly,  the
antiproliferative effect of PI3K inhibition was more pronounced
in BCR-ABL negative ALL cells: At concentrations close to the
IC50, LY294002 and NVP-BKM120 inhibited proliferation by a
median of 30% in ALL with an ABL-translocation (BCR-ABL+/
TEL-ABL+) and by 50% and 55% in BCR-ABL negative cells
(p=0.022 for NVP-BKM120) (Figure 3A).
Induction of cell death of ALL cells by both PI3K inhibitors
was likewise dose-dependent. BCR-ABL/TEL-ABL+ ALL cells
were more sensitive to induction of cell death than cells without
an ABL-translocation, with median of 39% vs. 20% cell death in
Figure 1.  Effect of ABL-directed tyrosine kinase inhibitors on BCR-ABL+ ALL LTCs.  Ph+ ALL cells with the T315I mutation
showed no growth inhibition (A) or induction of cell death (B) in response to any of the TKI. The BCR-ABL+ ALL-LTC PH was used
as a positive control (A and B).
Response to ABL-directed TKI of 6 non-mutated BCR-ABL+ LTCs (BV, CM, DW, KW, PH and VB) and the LTC KÖ with the T315I
mutation (C). Cell death was examined on day 4 of exposure to increasing concentrations of imatinib, dasatinib, and nilotinib.
(A, B, C) Cell proliferation was assessed by XTT assay and induction of cell death was measured by Annexin-V/propidium iodide
staining. The data shown represent the means + SD of 3 experimental replicates from one representative experiment out of 3
performed.
doi: 10.1371/journal.pone.0080070.g001
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BKM120  (Figure  3B).  The  antiproliferative  and  proapoptotic
effects of NVP-BKM120 were more pronounced than those of
LY294002, although the sensitivity of the individual ALL-LTCs
was  highly  variable.  In  order  to  determine  whether  the
heterogeneity  of  these  antiproliferative  and  proapoptotic
responses  were  associated  with  differential  effects  on  PI3K
signaling, we examined the phosphorylation levels of AKT, S6
and 4E-BP1, all of which are downstream of PI3K, in 5 ALL-
LTCs  representing  different  genetic  subtypes  of  ALL.  Jurkat
cells  have  a  constitutively  activated  PI3K  pathway  and  were
used as controls (Figure 3C and 3D).
Unexpectedly,  inhibition  of  PI3K  by  LY294002  and  NVP-
BKM120 was not associated with dephosphorylation of AKT at
Ser473, a surrogate marker for inhibition of PI3K activity, in the
majority  of  the  ALL-LTCs,  whereas  AKT  dephosphorylation
was observed in the control Jurkat cells. To determine whether
selective  inhibition  of  PI3K  had  an  effect  on  more  distal
components of this pathway, we examined the phosphorylation
status of S6 and 4E-BP1, two targets of mTORC1 which are
downstream of AKT. In the majority of ALL-LTCs and in the
control Jurkat cells, S6 phosphorylation was reduced in dose-
dependent manner in response to both LY294002 and NVP-
BKM120,  indicating  that  PI3K  inhibition  indeed  inhibited
mTORC1. In contrast, when ALL-LTCs were treated with these
PI3K inhibitors, 4E-BP1 was not dephosphorylated (Figure 3C
and 3D).
Thus, in ALL-LTCs, the magnitude of the antiproliferative and
proapoptotic effects of selective PI3K inhibition is independent
of the presence of an ABL translocation. This is consistent with
the  observation  that  the  effect  of  PI3K  inhibition  on  the
phosphorylation status of more distal components of the PI3K
pathway was also independent of an ABL-translocation. Among
BCR-ABL  positive  ALL-LTC,  their  sensitivity  to  ABL-directed
TKI  did  not  correlate  with  responsiveness  to  PI3K  inhibition.
The variable sensitivity of the LTCs to PI3K inhibition could not
be attributed to differences in the phosphorylation of AKT, S6
protein and 4E-BP1.
Inhibition of mTORC1 blocks cell proliferation without
inducing cell death irrespectively of BCR-ABL/TEL-ABL
status
The antiproliferative and proapoptotic effect of PI3K inhibition
occurred  in  conjunction  with  dephosphorylation  of  the  S6
protein,  a  downstream  target  of  mTORC1.  We  therefore
investigated  whether  selective  inhibition  of  mTORC1  by
RAD001  likewise  resulted  in  suppression  of  proliferation  and
induction of cell death in ALL cells. RAD001 strongly inhibited
phosphorylation of the S6 protein in the majority of ALL LTCs
and  Jurkat  cells,  but  not  of  4E-BP1  (Figure  4C).  This  was
associated with a dose-dependent inhibition of cell proliferation
ranging from 20%-70% at 25nM in the ALL-LTCs tested, with
maximum inhibition of cell growth at 100nM (Figure 4A). There
was  no  statistically  significant  difference  between  ALL  cells
with or without an ABL-translocation. In contrast, RAD001 did
not induce cell death of ALL cells from any of the LTCs even at
concentrations up to 10µM (Figure 4B). Thus, while selective
inhibition  of  PI3K  by  NVP-BKM120  and  of  mTORC1  by
RAD001 had the same differential effect on phosphorylation of
S6  protein  and  4E-BP1,  they  differed  considerably  in  their
ability to induce cell death. This suggests that in ALL, the effect
of PI3K signaling on survival and cell death is not mediated
solely by mTORC1, and that phosphorylation of the mTORC1
targets  S6  protein  and  4E-BP1  is  differentially  regulated.
Notably,  exposure  of  TEL-ABL+  cells  (VG)  to  RAD001  was
accompanied  by  a  compensatory  increase  in  AKT
phosphorylation (Figure 4C), a finding consistent with activation
of  negative  feedback  loops  as  a  consequence  of  mTORC1
inhibition.  This  effect  was  not  observed  in  any  of  the  other
BCR-ABL positive or negative cells.
Moreover, the different sensitivity of the individual ALL-LTCs
to  mTORC1  inhibition  does  not  correlate  with  the
Figure  2.    Impact  of  ABL-kinase  inhibition  on  PI3K/AKT/mTOR  signaling  in  BCR-ABL  and  TEL-ABL  positive  ALL
LTCs.  BCR-ABL+ (BV, PH, KW, CM, BV und DW), TEL-ABL+ (VG) and BCR-ABL- (HP, KR, RL, CR und SK) LTCs were treated
with 1µM Imatinib for 20h. Lysates of these cells were used for the detection of phosphorylated and total AKT, S6 and 4E-BP1 by
Western blotting. Because of the constitutively activated PI3K/AKT/mTOR pathway in Jurkat cells, lysates of untreated Jurkat cells
were used as positive controls and that of cells treated for 2h with 1µM Wortmannin (WM), a PI3K inhibitor, were used as negative
controls. β-Actin was used as loading control.
doi: 10.1371/journal.pone.0080070.g002
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determined by Western blotting.
Antiproliferative and proapoptotic activity of combined
inhibition of PI3K, mTORC1 and mTORC2 is
independent of an ABL-translocation
Whereas  both  RAD001  and  NVP-BKM120  resulted  in
comparable  dephosphorylation  of  S6  protein,  cell  death  was
induced  only  by  NVP-BKM120.  This  prompted  us  to  explore
Figure 3.  The impact of PI3K inhibition in B-ALL is independent of the presence of an ABL translocation.  BCR-ABL+ (BV,
PH,  KW,  CM,  BV  und  DW),  TEL-ABL+  (VG)  and  BCR-ABL-  (HP,  KR,  RL,  CR  und  SK)  LTCs  were  exposed  to  increasing
concentrations of the PI3K inhibitors LY294002 or NVP-BKM120. (A) Proliferation was measured after 4 days of drug treatment.
Comparing the proliferation rate of the ABL-translocated cells (BCR-ABL+/TEL-ABL+) with the BCR-ABL- cells shows no difference
in response to treatment with 10µM LY294002 (correspond approximately to the IC50). In contrast, exposure to 0.5µM NVP-BKM120
(correspond approximately to the IC50) resulted in a significantly stronger inhibition of proliferation of the BCR-ABL- cells (p=0.0221
(*)). (B) Cell death was measured after 4 days of drug treatment. The rate of cell death of the ABL-translocated cells (BCR-ABL+/
TEL-ABL+) was significantly higher than of BCR-ABL negative ALL (p=0.013 (*)) after exposure of 20µM LY294002 (corresponding
approximately to the IC50). Treatment with 2.5µM NVP-BKM120 showed no difference between ABL-translocated cells (BCR-ABL+/
TEL-ABL+) and the BCR-ABL- cells in terms of cell death induction (A, B) Cell proliferation was assessed by using XTT assay,
induction of cell death was measured by Annexin-V/propidium iodide staining. The data shown represent the means + SD of 3
experimental replicates from one representative experiment out of 3 performed.
(C) BCR-ABL+ (PH and BV) and BCR-ABL- (HP) LTCs were treated with increasing concentrations of LY294002 for 2h. (D) BCR-
ABL+ (PH, BV and KÖ), TEL-ABL+ (VG), BCR-ABL- (HP) and Jurkat cells were exposed to increasing concentrations of NVP-
BKM120 for 2h.
(C, D) Lysates of these cells were used for the detection of phosphorylated and total AKT, S6 and 4E-BP1 by Western blotting.
Lysates of untreated Jurkat cells were used as positive controls and those of cells treated with the PI3K inhibitor Wortmannin (WM)
for 2h at 1µM served as negative controls. Ponceau staining and β-Actin were used as loading control. d = DMSO control.
doi: 10.1371/journal.pone.0080070.g003
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PLOS ONE | www.plosone.org 6 November 2013 | Volume 8 | Issue 11 | e80070Figure 4.  The impact of mTORC1 inhibition in B-ALL is independent of the presence of an ABL translocation.  BCR-ABL+
(BV, PH, KW, CM, BV und DW), TEL-ABL+ (VG) and BCR-ABL- (HP, KR, RL, CR und SK) LTCs were exposed to increasing
concentrations of the mTORC1 inhibitor RAD001. (A) Proliferation and (B) cell death were measured after 4 days of drug treatment.
The (A) proliferation rate and (B) rate of cell death of the ABL-translocated cells (BCR-ABL+/TEL-ABL+) and the BCR-ABL- cells did
not differ in their response to treatment with RAD001 at 25nM or 5µM, respectively (corresponding approximately to the IC50) values
determined for growth inhibition and induction of apoptosis, respectively).
(A, B) Cell proliferation was assessed by XTT assay, induction of apoptosis was measured by Annexin-V/propidium iodide staining.
The data shown represent the means + SD of 3 experimental replicates from one representative experiment out of 3 performed.
(C) BCR-ABL+ (PH, BV and KÖ), TEL-ABL+ (VG), BCR-ABL- (HP) and Jurkat cells were treated with increasing concentrations of
RAD001 for 2h. Lysates of these cells were used for the detection of phosphorylated and total AKT, S6 and 4E-BP1 by Western
blotting.  Lysates  of  untreated  Jurkat  cells  were  used  as  positive  controls  and  those  of  cells  treated  with  the  PI3K  inhibitor
Wortmannin (WM) for 2h at 1µM were used as negative controls. β-Actin was used as loading control.
doi: 10.1371/journal.pone.0080070.g004
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mTORC2  and  mTORC1.  mTORC2  is  known  to  induce  cell
proliferation by providing a feedback loop for AKT activation,
which  results  in  the  phosphorylation  of  AKT  at  Ser473.  The
dual  PI3K/mTORC1/C2  inhibitors  NVP-BGT226  and  NVP-
BEZ235  dose-dependently  inhibited  proliferation  and  induced
cell death in all ALL-LTCs (Figure 5A and 5B). Based on their
IC50 values within the nanomolar range, both NVP-BGT226 and
NVP-BEZ235 were more potent in terms of growth inhibition
and induction of cell death than the selective inhibitors of PI3K
and mTORC1 respectively (Figure 5A and 5B). We observed
same effects with the mTORC1/C2 inhibitors Torin 1, PP242
and KU-0063794 however, IC50 values were in high nanomolar
range  for  inhibition  of  proliferation  and  micromolar
concentrations were needed for induction of cell death (Figures
S1A and S1B).
Treatment  with  NVP-BGT226  and  NVP-BEZ235  at
concentrations close to the IC50 (NVP-BGT226 [10nM], NVP-
BEZ235  [50nM]),  inhibited  proliferation  of  BCR-ABL  negative
LTCs  more  potently  than  that  of  BCR-ABL/TEL-ABL  positive
Figure 5.  The impact of combined PI3K, mTORC1 and mTORC2 inhibition in B-ALL is independent of the presence of an
ABL translocation.  BCR-ABL+ (BV, PH, KW, CM, BV und DW), TEL-ABL+ (VG) and BCR-ABL- (HP, KR, RL, CR und SK) LTCs
were exposed to increasing concentrations of the PI3K/mTORC1/C2 inhibitors NVP-BGT226 and NVP-BEZ235. (A) Proliferation
was measured after 4 days of drug treatment. Inhibition of proliferation by 10nM NVP-BGT226 (corresponding approximately to the
IC50) was more pronounced in the ABL-translocated cells (BCR-ABL+/TEL-ABL+) than in BCR-ABL- cells (p=0.0283 (*)). In contrast,
treatment with 50nM NVP-BEZ235 (corresponding approximately to the IC50) showed no difference between BCR-ABL+/TEL-ABL+
and BCR-ABL- cells. (B) Apoptosis was measured after 4 days of drug exposure. The rate of cell death induced by NVP-BEZ235 or
NVP-BGT226  was  not  significantly  different  in  ABL-translocated  cells  (BCR-ABL+/TEL-ABL+)  and  BCR-ABL-  cells  (A,  B)  Cell
proliferation was assessed by XTT assay, induction of cell death was measured by Annexin-V/propidium iodide staining. The data
shown represent the means + SD of 3 experimental replicates from one representative experiment out of 3 performed.
(C, D) BCR-ABL+ (PH, BV and KÖ), TEL-ABL+ (VG), BCR-ABL- (HP) and Jurkat cells were treated with increasing concentrations
of (C) NVP-BGT226 or (D) NVP-BEZ235 for 2h. Lysates of these cells were used for the detection of phosphorylated and total AKT,
S6 and 4E-BP1 by Western blotting. Lysates of untreated Jurkat cells were used as positive controls and those of cells treated for
2h with 1µM Wortmannin (WM) served as negative controls. β-Actin was used as loading control. d = DMSO control.
doi: 10.1371/journal.pone.0080070.g005
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(p=0.0283 10nM) (Figure 5A). No differences were detected for
the mTORC1/C2 inhibitors Torin 1, PP242 and KU-0063794 at
concentrations  close  to  the  IC50  (Figures  S1A  and  S1B).
Inhibition  of  PI3K/mTORC1/C2  by  NVP-BGT226  or  NVP-
BEZ235 induced cell death in a dose-dependent manner in all
LTCs  independently  of  the  presence  of  BCR-ABL/TEL-ABL
translocation with median rates of cell death of 60% and 45%,
respectively (Figure 5B). The same is true for the mTORC1/C2
inhibitors  Torin  1  and  PP242  except  for  the  mTORC1/C2
inhibitor  KU-0063794,  which  showed  a  significant  greater
induction  of  cell  death  in  BCR-ABL/TEL-ABL  positive  cells
compared to negative cells (p=0.0209 5µM) (Figures S1A and
S1B).
To determine why dual inhibitors targeting PI3K/mTORC1/C2
more  potently  suppressed  cell  proliferation  and  induced  cell
death  than  the  selective  inhibitors  of  PI3K  and  mTORC1,
respectively, we analyzed the phosphorylation level of AKT, S6
and  4E-BP1  in  ALL-LTCs  following  to  the  different  inhibitors
(Figure 5C and 5D).
In contrast to their effects on Jurkat cells, used as a positive
control,  the  dual  inhibitors  NVP-BGT226  and  NVP-BEZ235,
failed  to  dephosphorylate  AKT  in  ALL-LTCs,  similar  to  the
selective  PI3K  and  mTORC1  inhibition.  S6  protein,
downstream of AKT, was dephosphorylated following exposure
to  both  dual  (NVP-BGT226,  NVP-BEZ235)  and  selective
inhibitors (NVP-BKM120, RAD001) in the majority of ALL cells
examined. In contrast, dephosphorylation of 4E-BP1, likewise
downstream  of  AKT,  was  observed  in  response  to  ATP-
competitive  PI3K/mTOR  and  mTORC1/C2  inhibitors  (Figure
S2)  but  not  to  selective  inhibitors  of  PI3K  and  the  allosteric
mTORC1  inhibitor  RAD001.  This  differential  response  was
noted in both Jurkat and ALL-LTC and was also independent of
the  ABL-translocation  status.  The  dose-response  of  4E-BP1
dephosphorylation  revealed  greater  potency  of  NVP-BGT226
compared to NVP-BEZ235 and was associated with a greater
proapoptotic effect of NVP-BGT226.
Together, these data suggest that inhibition of both mTORC1
and mTORC2 by ATP-competitive inhibitors contributes to the
antiproliferative and proapoptotic effects of the dual inhibitors.
At  inhibitor  concentrations  that  induce  cell  death  and
dephosphorylation of 4EBP1, Ser473 AKT does not appear to
be  involved,  suggesting  a  role  of  other  PI3K-related  kinases
such as SGK [41].
Pronounced antiproliferative and proapoptotic activity
of dual PI3K/mTORC1/mTORC2 inhibitors in ALL
The greater antiproliferative and proapoptotic activity of dual
(ATP-competitive) inhibitors of PI3K and mTOR, in conjunction
with  the  exclusively  antiproliferative  effects  of  allosteric
mTORC1 inhibition, raised the possibility of a contributory role
of mTORC2. To determine whether mTORC2 inhibition indeed
contributes  to  the  antileukemic  effect  of  the  dual  inhibitors
NVP-BGT226  and  NVP-BEZ235,  we  compared  the
antileukemic  activity  of  these  compounds  with  that  of  the
selective  inhibitors  alone  and  in  combination.  As  shown  in
Figure 6A, inhibition of PI3K by the ATP-competitive inhibitor
NVP-BKM120  in  conjunction  with  the  allosteric  mTORC1
inhibitor  RAD001  has  a  greater  antiproliferative  effect  than
treatment  with  the  individual  inhibitors  alone.  However,
concurrent  inhibition  of  PI3K  and  mTORC1  had  a  lesser
antiproliferative  effect  than  the  combined  inhibition  of  PI3K,
mTORC1 and mTORC2 achieved with the dual inhibitors NVP-
BGT226  and  NVP-BEZ235,  respectively.  Cell  death  was  not
enhanced  by  combining  the  selective  inhibitors,  whereas
simultaneous  inhibition  of  PI3K,  mTORC1  and  mTORC2  by
ATP competitive inhibitors considerably enhanced cell death,
most pronounced for NVP-BGT226 (Figure 6B).
To  analyze  whether  inhibition  of  mTORC2  affects  the
phosphorylation  level  of  the  S6  protein  and  4E-BP1,  we
performed western blot analysis after exposure of the different
drug combinations described above. As shown in Figure 6C,
individual as well as combined PI3K and mTORC1 inhibition
and combined PI3K, mTORC1 and mTORC2 inhibition results
in  the  dephosphorylation  of  the  S6  protein,  as  expected.  In
contrast,  allosteric  inhibition  of  mTORC1,  alone  or  combined
with  a  selective  ATP-competitive  inhibitor  of  PI3K  had  no
impact on 4E-BP1 phosphorylation, whereas the simultaneous
inhibition  of  mTORC1  and  C2  or  of  PI3K,  mTORC1  and
mTORC2  by  ATP-competitive  inhibitors  resulted  in  a
dephosphorylation of 4EBP1 (Figure 6C and Figure S2).
Taken  together,  these  data  indicate  that  the  roles  of
mTORC1 and mTORC2 in regulating proliferation and survival
of  B-ALL  cells  are  independent  of  an  ABL-translocation.
Furthermore, these data are consistent with a contribution of
mTORC1  and/or  mTORC2  to  regulation  of  4E-BP1
phosphorylation.
Discussion
Functional studies involving primary ALL cells are hampered
by  the  well-known  inability  to  maintain  human  ALL  blasts  in
short-term  culture  and  the  high  initial  rate  of  cell  death.  We
have previously reported a unique cell culture system enabling
long-term  culture  of  leukemic  lymphoblasts  obtained  from
patients  with  ALL.  These  cultures  represent  different
genetically defined ALL subtypes, i.e. leukemias harboring the
BCR-ABL,  TEL-ABL  or  E2A-PBX1  translocation,  or  no
recurring genetic abnormality [38,39]. Our evaluation of the role
of  the  PI3K  pathway  in  leukemic  cell  growth  and  survival
focused initially on BCR-ABL expressing leukemias, as PI3K
signaling  has  been  strongly  implicated  in  malignant
transformation and development of TKI-resistance in Ph+ ALL
[3,6,14–16].  Effective  suppression  of  PI3K  signaling  utilizing
two potent, dual specificity ATP-competitive compounds, both
of  which  are  pan-PI3K  inhibitors  and  additionally  block  the
mTOR  complexes  C1  and  C2  downstream  of  PI3K  (NVP-
BGT226 and NVP-BEZ235), potently inhibits proliferation and
induces  cell  death  in  BCR-ABL  positive  and  in  TEL-ABL
positive  ALL  at  nanomolar  concentrations.  The  magnitude  of
the antileukemic effects did not differ in ALL cells that displayed
high  or  intermediate  sensitivity  to  the  ABL-directed  kinase
inhibitors  imatinib,  nilotinib  and  dasatinib,  or  were  resistant
either  due  to  the  T315I  TKD  mutation  (in  KÖ  cells)  or  non-
mutational  resistance  (in  BV  cells).  In  conjunction  with
published data showing that blockage of the PI3K pathway with
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survival, clonogenic growth and differentiation of normal CD34
positive cells [42], the profound antileukemic activity against Ph
+ ALL indicates a pivotal role of the PI3K pathway in our ALL
cells. This is consistent with the generally accepted activation
of PI3K by the BCR-ABL oncoprotein, but does not exclude its
involvement in BCR-ABL negative ALL as well. In fact, aberrant
activation of the PI3K pathway has been shown to be one of
the  most  frequent  perturbations  of  signaling  pathways  in
malignancies, including leukemias [5–7]. Our results with BCR-
ABL/TEL-ABL negative ALL cells demonstrate for the first time
that  the  antiproliferative  and  proapoptotic  effects  of  the  dual
inhibitors NVP-BGT226 and NVP-BEZ235 are comparable to
those in ABL-translocated ALL. The mechanism by which the
PI3K  pathway  is  activated  in  ALL  cells  is  presently  unclear.
Possible  mechanisms  include  constitutive  activation  of
upstream signaling pathways, e.g. by BCR-ABL or inactivation
of  PTEN  as  shown  in  T-ALL  lines,  activating  mutations  of
NOTCH1,  RAS,  or  of  the  PI3K  itself  as  in  B-lymphomas
[43–45]. Activating mutations of PI3K and AKT occur frequent
in solid tumors but are rarely observed in leukemias [46–49].
Nevertheless, we sequenced the hot-spot regions of PIK3CA
and  screened  for  the  E17K  mutation  in  the  AKT1  gene,
confirming that no mutations are present in any of the 13 ALL-
LTCs  (data  not  shown).  Mutations  or  epigenetic  silencing  of
PTEN  occur  in  many  tumor  types  including  Ph+  ALL  [50],
resulting  in  enhanced  phosphorylation  of  AKT  by  increasing
cellular  levels  of  PIP3.  We  found  no  evidence  of  decreased
PTEN expression in our ALL cells, indicating that diminished
PTEN activity is not the cause of AKT activation.
Our  results  raise  the  question  which  of  the  individual
components  of  the  PI3K/AKT/mTOR  pathway  are  most
relevant for supporting leukemic cell growth and thus are the
most attractive targets for therapeutic intervention. To dissect
the  relative  contributions  of  PI3K  and  the  mTORC1  and
mTORC2 complexes, we exposed ALL-LTCs to the allosteric
mTORC1 inhibitor RAD001 and the selective panPI3K inhibitor
NVP-BKM120,  both  of  which  are  being  evaluated  for  anti-
neoplastic activity in clinical trials. Blocking only mTORC1 by
RAD001 failed to induce cell death in any of the ALL cells, and
had  a  moderate  antiproliferative  effect,  which  was  most
conspicuous  in  the  TEL-ABL  expressing  ALL  cells.  These
Figure  6.    The  impact  of  additional  inhibition  of  mTORC2  on  combined  PI3K  and  mTORC1  inhibition  in  B-ALL  is
independent of the presence of an ABL translocation.  BCR-ABL+ (PH and BV) and BCR-ABL- (HP) cells were treated with
0.5µM or 2µM NVP-BKM120 (PI3K inhibitor), 0.5µM or 2µM RAD001 (mTORC1 inhibitor) alone or in combination. For combined
PI3K/mTORC1/C2 inhibition, cells were treated with 0.5µM or 2µM of NVP-BGT226 or NVP-BEZ235. (A) Proliferation and (B) cell
death were measured after 4 days of drug treatment.
(A, B) Cell proliferation was assessed by XTT assay, induction of cell death was measured by Annexin-V/propidium iodide staining.
The data shown represent the means + SD of 3 experimental replicates from one representative experiment out of 3 performed.
(C) Lysates were prepared after 2h of drug treatment for the detection of phosphorylated and total AKT, S6 and 4E-BP1 by Western
blotting. Lysates of untreated Jurkat cells were used as positive controls, those of cells treated for 2h with 1µM Wortmannin (WM)
were used as negative controls. β-Actin was used as loading control.
doi: 10.1371/journal.pone.0080070.g006
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disease entities, which demonstrate that RAD001 has primarily
antiproliferative effects [25,27,32]. This suggests that allosteric
inhibition of mTORC1 alone by RAD001 is unlikely to be an
effective antileukemic approach in ALL. Suppression of PI3K
activity  by  the  selective  inhibitor  NVP-BKM120  had  both
antiproliferative  and  significant  cell  death-inducing  activity  in
the  ALL-LTC,  irrespective  of  their  underlying  genetic
abnormalities. The lack of proapoptotic activity of RAD001 or
known  rapalogs  may  be  attributable  to  the  activation  of  a
feedback loop that leads to enhanced phosphorylation of PI3K
and subsequent activation of AKT, which in turn counteracts
the growth inhibitory effect of mTORC1 inhibition [27–30]. The
impact  of  this  feedback  loop  on  PI3K  activity  should  be
abrogated  by  blocking  this  pathway  proximally,  e.g.  by  the
selective  PI3K  inhibitor  NVP-BKM120.  Indication  of  such  a
feedback  loop  in  our  ALL  cells  is  provided  most  visibly  in
experiments using the TEL-ABL positive ALL-LTC VG, in which
exposure  to  RAD001  resulted  in  a  dose-dependent
augmentation of AKT phosphorylation. Accordingly, combining
inhibitors that act both distally (e.g. RAD001) and proximally
(e.g. NVP-BKM120) is a rational approach towards maximizing
the antileukemic efficacy of PI3K pathway inhibition. When we
combined  these  two  compounds,  the  antiproliferative  activity
was  profoundly  enhanced  in  comparison  with  the  individual
inhibitors,  but  we  observed  no  induction  of  cell  death.  We
therefore postulate that the poor proapoptotic activity of NVP-
BKM120 and RAD001 in nanomolar concentrations could be
due to their inability to block mTORC1 and mTORC2. Another
potentially contributing factor is the limited suppressive effect of
allosteric  inhibitors  on  mTORC1,  resulting  in  compensatory
activation  of  feedback  loops  that  may  not  be  seen  in  the
presence  of  ATP-competitive  inhibitors  of  mTORC1  [51].
However,  no  clear  evidence  for  activation  of  these  well
described feedback loops was noted in our experiments, based
on the absence of increased AKT phosphorylation. While the
ribosomal  protein  S6  is  a  S6K1  substrate  and  its
phosphorylation is used as a biomarker of mTORC1 activity,
the  regulation  of  4E-BP1  is  controversial  [17,52].  We
demonstrate dephosphorylation of 4E-BP1 in response to ATP-
competitive inhibitors of mTORC1 and C2 but not to allosteric
mTORC1 inhibition or inhibition of PI3K. These data are not
compatible  with  a  recently  published  model  which  proposes
that 4E-BP1 is under the direct control of PI3K [52]. While our
data  implicate  mTOR  as  an  important  mediator  of  4E-BP1
phosphorylation, we can not discriminate between the relative
contributions of mTORC1 and mTORC2 because of the lack of
selective,  ATP-competitive  inhibitors  of  these  two  mTOR
components.  Thus,  it  is  possible  that  both  mTORC1  and
mTORC2 phosphorylate 4E-BP1 so that inhibition of either one
would not dephosphorylate 4E-BP1 because of compensatory
signaling by the other. These divergent findings may reflect the
different  cell  context  in  the  various  studies,  and  support  a
model  in  which  4E-BP1  is  regulated  by  both  mTORC1  and
mTORC2  in  the  setting  of  B-lineage  acute  lymphoblastic
leukemia.  In  conjunction  with  the  biologic  data  presented
above, inhibition of leukemic cell proliferation and induction of
cell death was by far most pronounced with the dual inhibitors
NVP-BEZ235  and  NVP-BGT226  that  resulted  in  4E-BP1
dephosphorylation. This is consistent with their ability to inhibit
mTORC2  in  addition  to  mTORC1  and  PI3K,  with  the  caveat
that  results  based  on  pharmacologic  rather  than  genetic
inhibition  may  be  influenced  by  off-target  effects  of  the
inhibitors used.
We did not specifically examine and compare the impact of
selective AKT inhibition on leukemic cell growth and cell death.
By  Western  blotting,  AKT  showed  only  a  minimal  degree  of
phosphorylation at position Ser473 in the ALL-LTC compared
to the Jurkat cell line. This is similar to published data showing
weak AKT phosphorylation in p190BCR-ABL transformed murine
pro/pre-B  cells,  despite  these  cell´s  dependency  on  PI3K
signaling  [53].  More  importantly  however,  we  observed  no
consistent  dephosphorylation  of  AKT  following  inhibition  of
either BCR-ABL or PI3K signaling, raising the possibility that
other targets within the PI3K signaling pathway may be more
important than AKT. In numerous cancer cell lines, oncogenic
PI3K  activation  has  indeed  recently  been  shown  to  be
mediated  not  by  AKT  but  by  SGK3,  another  kinase  that
activates mTORC1 [41], suggesting that AKT itself may be only
one  of  several  relevant  targets  for  antileukemic  interventions
targeting the PI3K pathway. However, Levy et al. [54] recently
reported  that  the  selective  pan-AKT  inhibitor  GSK690693
possessed potent antiproliferative activity in 12 of 15 B-lineage
ALL cell lines, including two that were BCR-ABL positive. Cell
death was induced in all 3 T-ALL cells tested and in one BCR-
ABL  negative  ALL  cell  line.  These  observations  argue  for  a
significant  contributory  role  for  AKT  signaling  in  ALL  growth,
and  lend  support  to  our  findings  that  PI3K  signaling  is  a
relevant  antileukemic  target  not  only  in  BCR-ABL  positive
leukemias,  but  also  in  other  subtypes  of  ALL.  As  a  caveat,
comparison of the biologic effects of the various pharmacologic
inhibitors  needs  to  consider  that  off-target  effects  may
contribute to the relative potencies of the agents used and may
be  confounding  factors  when  interpreting  the  interactions
between different agents. For example, a recent publication by
Shortt J et al. [55] demonstrates that BEZ235 also inhibits the
PI3K-related  kinases  ATM  and  DNA-PK  at  nanomolar
concentrations.  Thus,  it  is  possible  that  the  anti-apoptotic
activity of BEZ235, and possibly of BGT266, is not exclusively
due to inhibition of canonical PI3K signaling but to effects on
other non-mTOR, PI3K- related kinases.
In conclusion, simultaneous inhibition of PI3K, mTORC1 and
mTORC2  by  the  dual  inhibitors  NVP-BEZ235  and  NVP-
BGT226 exerts profound antileukemic activity against a broad
spectrum of B-precursor ALL, irrespective of genetic subtype
and – in the case of BCR-ABL positive ALL – their degree of
responsiveness  or  resistance  to  clinically  established  ABL-
kinase inhibitors. Combined inhibition of PI3K, mTORC1 and
mTORC2 enhances the induction of cell death in a subset of
these  leukemias.  In  the  cellular  context  of  ALL,
dephosphorylation  of  4E-BP1  is  observed  in  response  to
inhibition  of  both  mTORC1  and  mTORC2,  but  is  not
necessarily associated with induction of cell death. Our data
provide  a  strong  preclinical  rationale  for  clinical  studies
exploring these compounds as treatment for ALL, but suggest
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biomarkers in clinical trials of PI3K pathway inhibitors in ALL.
Supporting Information
Figure S1.  The impact of combined mTORC1 and mTORC2
inhibition in B-ALL is independent of the presence of an
ABL  translocation.  BCR-ABL+  (BV,  PH,  KW,  CM,  BV  und
DW),  TEL-ABL+  (VG)  and  BCR-ABL-  (HP,  KR,  RL,  CR  und
SK)  LTCs  were  exposed  to  increasing  concentrations  of  the
mTORC1/C2 inhibitors KU-0063794, PP242 und Torin 1. (A)
Proliferation was measured after 4 days of drug treatment. The
proliferation  rate  of  the  ABL-translocated  cells  (BCR-ABL+/
TEL-ABL+)  and  the  BCR-ABL-  cells  did  not  differ  in  their
response to treatment with KU-0063794, PP242 and Torin 1 at
1µM  or  0.1µM,  respectively  (corresponding  approximately  to
the IC50).
(B) Cell death was measured after 4 days of drug treatment.
The rate of cell death of the ABL-translocated cells (BCR-ABL
+/TEL-ABL+)  was  significantly  higher  than  of  BCR-ABL
negative  ALL  (p=0.0209  (*))  after  exposure  of  5µM
KU-0063794  (corresponding  approximately  to  the  IC50).
Treatment  with  5µM  PP242  or  0.1µM  Torin  1  showed  no
difference  between  ABL-translocated  cells  (BCR-ABL+/TEL-
ABL+) and the BCR-ABL- cells in terms of cell death induction.
(A, B) Cell proliferation was assessed by XTT assay, induction
of  cell  death  was  measured  by  Annexin-V/propidium  iodide
staining.  The  data  shown  represent  the  means  +  SD  of  3
experimental replicates from one representative experiment out
of 2 performed.
(TIF)
Figure S2.  The impact of combined mTORC1 and mTORC2
inhibition  in  B-ALL  on  AKT,  S6  and  4E-BP1
phosphorylation. BCR-ABL+ (PH, BV) and Jurkat cells were
treated with increasing concentrations of KU-0063794, PP242,
Torin  1  for  2h.  Lysates  of  these  cells  were  used  for  the
detection of phosphorylated and total AKT, S6 and 4E-BP1 by
Western blotting. Lysates of untreated Jurkat cells were used
as positive controls and those of cells treated for 2h with 1µM
Wortmannin  (WM)  served  as  negative  controls.  β-Actin  was
used as loading control. d = DMSO control.
(TIF)
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